Clinical Trial Update: A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating recombinant anti-PD-1 antibody (609A) with doxorubicin for metastatic/unresectable soft tissue sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anti-PD-1 monoclonal antibody (609A) recombinant humanized (PD-1 inhibitor (609A))
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Sarcoma, Soft Tissue | Phase 2 | Status: UNKNOWN